Showing 5081-5090 of 9940 results for "".
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”
- Business News: Lilly, Dermira Acquisition Completehttps://practicaldermatology.com/news/business-news-lilly-dermira-acquisition-complete/2460287/Eli Lilly and Company has completed its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated in a Phase 3 clinical development
- Neuromodulators and Fillers Top RealSelf's List of Most Worth It Procedures of 2020https://practicaldermatology.com/news/neuromodulators-and-fillers-top-realselfs-list-of-most-worth-it-procedures-of-2020-1/2460272/A total of 15 nonsurgical and 37 surgical procedures earned Real Self’s Most Worth It designation for 2020. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Wo
- Alma Rolls Out Opus Plasmahttps://practicaldermatology.com/news/alma-rolls-out-opus-plasma/2460264/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- DermTech’s Pigmented Lesion Assay Receives Medicare Coveragehttps://practicaldermatology.com/news/dermtechs-pigmented-lesion-assay-receives-medicare-coverage/2460241/The Medicare Administrative Contractor Palmetto GBA MolDx issued a final local coverage determination for DermTech, Inc.'s Pigmented Lesion Assay (PLA). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more cli
- FDA Approves Ortho Dermatologic’s Arazlo Lotion for Acnehttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-arazlo-lotion-for-acne/2460238/The FDA has approved the New Drug Application for ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. Ortho Dermatologic’s ARAZLO is the first tazarotene acne treatment available in a lotion form,
- Baring Private Equity Asia Agrees to Acquire Lumenishttps://practicaldermatology.com/news/baring-private-equity-asia-agrees-to-acquire-lumenis-1/2460222/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen